Effects of erythropoietin in improving function of spinal cord injury
Introduction: Acute Spinal Cord Injury (ASCI) is one of the most common and important disorders in the field of neurosurgery. Progress achieved in relation to the care provided to repair spinal cord injuries have been taken from ancient times to the present day. Recently Neuroprotective therapies have attracted a lot of staff to approach the patient. Research scientists have shown that there is a possibility of recovery after spinal cord injury. Many pharmacological agents, Erythropoietin, in this field are used to reduce secondary damage after the primary insult and try to preserve nerve tissue. The aim of this study was to investigate the effect of Erythropoietin on sensory and motor status of patients with acute spinal cord injury. Materials and Methods: In this clinical trial, 60 patients with acute spinal cord injury in the Frankel classification, the category A to C, and the selection of matched Frankel class into two groups A and B (each group consisted of 30 patients) was done. Group A underwent conventional treatment received methylprednisolone, were used erythropoietin and were compared after 4days,6-months intervals in terms of complete and incomplete cord injury status with group B (that underwent only conventional treatment such as methylprednisolone). Results: In our study of two groups there were 16 patients with complete spinal cord injury and 44 patients were had incomplete SCI. In the period of 4 days after the onset of the study, patients with complete SCI in case and control group did not recover. In Patients with incomplete spinal cord injury in case group 13 of 21 patients (62%) and 2 of 23 patients (9%) in the control group were cured. In the period of 6 months after the study, 2 of 8 patients (25%) in case group with complete cord had recovery. In the control group of patients with complete spinal cord injury didn't have any recovery. Also in incomplete SCI 12 of 19 patients (63%) in case group and 5 of 21 patients (23%) in the control group were cured. Conclusion: Based on the results obtained improvement in muscle strength and sensory classified according to Frankel in patients receiving erythropoietin in period between 4 days and 6 months can be seen that the difference significant with the control group (P<0.0001). So Frankel class B, C to C- D- E Frankel grade was reached after recovery.
Keywords: Acute spinal cord injury; Classification Frankel; Erythropoietin; Methylprednisolone
Wilson JR, Cho N, Fehlings MG. (2014). Acute Traumatic Spinal Cord Injury: Epidemiology, Evaluation, and Management.Spine Surgery Basics. Springer. p. 399-409.
EbrahimEltoray.translate by Abbas Kashi.(1388).Raveshha and osoltebbinokhaii.Iran
VIVES MJ, GARFIN SR, ABITBOL JJ, Vaccaro AR. (2013). Timing of Surgery Following Spinal Cord Injury. Fractures of the Cervical, Thoracic, and Lumbar Spine, 62.
Hall ED, Springer JE. (2004). Neuroprotection and acute spinal cord injury: a reappraisal. NeuroRx, 1(1), 80-100.
Fisher M. (2011). New approaches to neuroprotective drug development. Stroke, 42(1 suppl 1), S24-S27.
H.RICHARD WINN,MD.professor and director of neurosurgery .YOUMANS NEUROLOGICAL SURGERY.SIXTH EDITION.
DavarAltafi, Mahdi Farhoodi. Therapeutic effects of intravenous erythropoietin in improving function outcome of intacerebral hemorrhage paitients , Tabriz university of medical science, faculty of medicine Tabriz, Iran,2010,
Shah RR, Tisherman SA. (2014). Spinal cord injury.Imaging the ICU Patient.Springer. p. 377-80.
Westgren N, Levi R. (1998). Quality of life and traumatic spinal cord injury.Archives of physical medicine and rehabilitation, 79(11), 1433-9.
Firth AM, Haldane SL. (1999 Mar 1). Development of a scale to evaluate postoperative pain in dogs. J Am Vet Med Assoc, 214(5), 651-9.
JelkmannW,Hellwing-Burgel T.2001 Biology of erythropoietin. AdvExp Med Biol 502:169-187.
Kobayashi T,YansaH,IwanagaT,Sasa;IR,Nagao M.2002 Epididymis is a novel site of erythropoietin production in mouse reproductive organs.BiochemBiophys Res Commun 296:145-151.
Patel NS,SharplesEJ,CuzzocreaS,ChatterjeePK,BrittiD,YaqoobMM,Theimermann C.2004Pretreatment with EPO reduses the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo.Kidney In 66:983-989.
Brines M,Cerami A.2005 Emerginig biological roles for erythropoietin in the nervous system.Nat Rev Neurosci 6:484-494.
Dame C,JuulSE,Christensen RD.2001 The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotectivepotential.Biol Neonate 79:228-235.
FANG Xiang – qian,FAN Shun – wu,GUChuan – long. protection of erythropoietin on experimental spinal cord injury by reducing the expression of thrombospondin 6 – and transfprming growth factor- beta, . ,department of orthopaedics sir runshau hospital, Zhejiany university , Hang zhau, China 2009 , jula .
Arishima, yoshiya MD, seyoguchi Takao MD, Yamoaura, Ichiro MD,Yone,KazunoriMD,Komya,setsuro MD. preventive effect of Erythropoietin on spinal cord cell apoptosis following acute tramatic injury in rats., 2006 oct.
SeyfriedDM,HanY,YangD,DingJ,Chopp M.2004 Erythropoietin promotes neurological recovery after intracerebral hemorrhage in rats.Int J Stroke.Auge :4(4):250-6.
Witko-SarsatV,RieuP,Descamps-LatschaB,LesavraP,Halbwachs-Mecarelli L.2000 Neutrophils:molecules,functions and pathophysiological aspects.Lab Invest 80:617-653.
Banks WA,JumbeNL,FarrellCL,NiehoffML,Heatherington AC.2004 Passage of erythropoietin ahents across the blood- brain barrier:a comparison of human and murine erythropoietin and the analog darbepoetinalfa.Eur J Pharmacol 505:93-10.
RecnyMA,ScobleHA,Kim Y.1987 Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin identification of des-arginine 166 erythropoietin .J BioChem 262:17156-17163.
Lipton P.1999 Ischemic cell death in the brain neurons.Physiol Rev 79:1431-1568.
Digicayliohlu M, BichetS,MartiHH,WengerRH,RivasLA,BauerC,Gassmann M.1995 Localization of specific erythropoietin binding sites in defined areas of the mouse brain.ProcNatlAcadSciUsa 92:3717-3720.
AnagnostouA,LeeES,KessimianN,LevinsonR,Steiner M.2006erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells.ProcNatlAcadSci USA 87:5978-5982.
Martinez-Estrada OM,Rodriguez-MillanE,Gonzalez-De Vicente E,ReinaM,VIlaroS,Fabre M.2..3 Erythropoietin protects the in vivo blood brain barrier against VEGF-induced permability.Eur J Neurosci 18:2538-2544.
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 4.0 International License.
2013-2016 (CC-BY) Australian International Academic Centre PTY.LTD.
Advances in Bioscience and Clinical Medicine